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A generic site-specific conjugation method that generates a homogeneous product is of utmost importance in tracer
development for molecular imaging and therapy. We explored the protein-ligation capacity of the enzyme Sortase A
to label camelid single-domain antibody-fragments, also known as nanobodies. The versatility of the approach was
demonstrated by conjugating independently three different imaging probes: the chelating agents CHX-A"-DTPA and
NOTA for single-photon emission computed tomography (SPECT) with indium-111 and positron emission tomogra-
phy (PET) with gallium-68, respectively, and the fluorescent dye Cy5 for fluorescence reflectance imaging (FRI). After
a straightforward purification process, homogeneous single-conjugated tracer populations were obtained in high
yield (30–50%). The enzymatic conjugation did not affect the affinity of the tracers, nor the radiolabeling efficiency
or spectral characteristics. In vivo, the tracers enabled the visualization of human epidermal growth factor receptor 2
(HER2) expressing BT474M1-tumors with high contrast and specificity as soon as 1 h post injection in all three imag-
ing modalities. These data demonstrate Sortase A-mediated conjugation as a valuable strategy for the development
of site-specifically labeled camelid single-domain antibody-fragments for use in multiple molecular imaging
modalities. Copyright © 2016 John Wiley & Sons, Ltd.
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1. INTRODUCTION
The conjugation of a label to a targeting agent is a pivotal step
in the generation of high quality imaging tracers and therapeu-
tic agents. The classical methods for protein conjugation to the
side chain ɛ-amine group of lysine residues or sulfhydryl group
of cysteine residues are often applied, but have their limitations.
Antibodies and antibody-derived fragments usually have several
solvent-exposed lysines making it difficult to control where and
how many labels will be conjugated (1). Moreover, the occur-
rence of a lysine residue in or near the antigen-binding site
can lead to impairment of the targeting agent upon conjugation
(2,3). The resulting heterogeneous tracer populations can be
avoided by, alternatively, introducing an unpaired cysteine
within the targeting agent for site-specific conjugation. How-
ever, this strategy requires a reduction step with careful titration
of the reducing agent, to liberate the introduced cysteine
residue without reducing intradomain disulfide bonds that are
crucial for stability, and which can result in unwanted reduction
side-products (4,5).
Several alternatives for site-specific conjugation are being
investigated, including the modification of glycans, the incor-
poration of unnatural amino acids, and the use of
chemoenzymatic reactions (6). In this work we explored the
use of Sortase A (SrtA), a transpeptidase derived from Staphylo-
coccus aureus that naturally catalyses the anchoring of cell wall
proteins to the peptidoglycan layer of the bacterial cell (7).
Gradually the recombinant form of the enzyme found its way
into many biotechnological applications because of the
straightforward introduction of a bioorthogonal functionality
into a protein-of-interest (8–10). The transpeptidation follows
a two-step reaction mechanism (Fig. 1A). First, SrtA cleaves
the polypeptide backbone of the substrate protein at the posi-
tion where the SrtA recognition motif (sortag) LPXTG was incor-
porated, with formation of an acyl-enzyme intermediate.
Subsequently, a new peptide bond is formed between the thre-
onine residue in the sortag and the N-terminal glycine of a nu-
cleophilic probe, containing the bioorthogonal functionality.
Key advantages of the system are: the simple production of
the recombinant enzyme in substantial amounts, its flexibility
towards its substrates, and the required presence of only very
short peptides in these substrates (the sortag LPXTG in the
target protein and a nucleophilic N-terminal oligoglycine within
the biorthogonal probe).
Here we describe a generic strategy for SrtA-mediated site-
specific labeling of camelid single-domain antibody-fragments
(sdAbs) to develop proficient reagents for non-invasive, in vivo
molecular imaging and therapy. A sdAb, also called VHH or
nanobody, is the recombinantly isolated antigen-binding do-
main of heavy-chain-only antibodies that occur in species of
the Camelidae family (11). Its small size (12–15 kDa) and high
specificity and affinity for its cognate antigen make it a success-
ful targeting agent for diagnostic imaging and targeted radionu-
clide therapy (12–14). Since a variety of radioisotopes and
fluorescent dyes are available, access to a generic conjugation
strategy is highly desired. The use of SrtA-mediated conjugation
for the site-specific labeling of sdAbs was demonstrated by
functionalizing the human epidermal growth factor receptor 2
(HER2)-targeting sdAb 2Rs15d independently with three differ-
ent labels. The functionality of the new tracer constructs was
subsequently validated in vitro and in vivo in tumor-targeting
experiments with multiple imaging modalities.
2. RESULTS
2.1. Design of the reaction substrates
The use of SrtA to conjugate a bioorthogonal probe to a protein-
of-interest requires only limited adaptations of these reaction
substrates. The target protein needs to possess a sortag (LPXTG)
at the desired conjugation site and the bioorthogonal probe, in
this case a chelating agent or fluorescent dye, needs to contain
a nucleophilic N-terminal glycine. The enzyme itself is produced
as a hexahistidine-tagged (His-tagged) recombinant protein
(Supplementary material and methods).
We explored the SrtA-mediated labeling strategy with the
HER2-targeting sdAb 2Rs15d and the non-targeting control sdAb
BcII10 as model compounds. Both sdAbs were expressed with a
C-terminal sortag (LPETG), followed by a His-tag (Fig. 1A). The
His-tag facilitates the purification of the sdAb via immobilized
metal affinity chromatography (IMAC) during production, but is
eliminated upon SrtA-mediated cleavage.
To demonstrate the versatility of SrtA-mediated conjugation in
the context of molecular imaging, we synthesized three different
nucleophilic imaging probes containing the chelating agents
CHX-A"-DTPA or NOTA, for use in single-photon emission com-
puted tomography (SPECT) and positron emission tomography
(PET), respectively, or the fluorescent dye Cy5 (excitation:
650 nm, emission: 670 nm), for use in fluorescence reflectance
imaging (FRI) (Fig. 2) (Supplementary material and methods). In
a first step the pentapeptide H-GGGYK-NH2 was synthesized
using standard solid phase peptide synthesis. Besides the
N-terminal triglycine, we included a tyrosine residue for its UV
absorbance property at 280 nm and a lysine residue for attach-
ment of the chelating agent or fluorescent dye. Next, we conju-
gated CHX-A"-DTPA-NCS, NOTA-NCS or Cy5 to the side chain
ɛ-amine of the lysine residue of the pentapeptide. The resulting
nucleophilic imaging probes were purified via reverse-phase
HPLC (RP-HPLC) and subsequently lyophilized.
2.2. SrtA-mediated conjugation
The SrtA-mediated conjugation was optimized with sdAb
2Rs15d-sortag and CHX-A"-DTPA as the substrates. The sdAb
concentration was kept constant while the SrtA and imaging
probe concentrations, as well as the reaction time were varied
(Fig. S1). To evaluate the reaction efficiency, advantage was
taken from the elimination of the His-tag upon conjugation. In
an anti-His-tag Western blot the consumption of sdAb starting
product is visualized by a decreasing intensity of the sdAb band.
An overnight reaction with a molar ratio sdAb : SrtA : nucleo-
philic imaging probe of 1:3:30 was found most optimal. Conse-
quently this condition was used for conjugation of the three
nucleophilic imaging probes. For each of the probes the reaction
efficiency was determined in Western blot (Fig. 3). Comparison of
the intensity of the sdAb band in lane 3 (reaction mixture with all
three components) to lane 1 (reference lane with only sdAb)
indicated that the chemo-enzymatic reaction consumed at least
75% of the sdAb substrate, regardless the imaging probe used.
In a control reaction sdAb and SrtA were incubated without
the imaging probe (lane 2). In this case the reaction could not
proceed beyond the acyl-enzyme intermediate (SrtA bound to
sdAb), resulting in a more intense band of the intermediate (vis-
ible by the His-tag of SrtA) and less consumption of the sdAb
substrate. In the case of Cy5, the final conjugated product
Cy5-2Rs15d could also be visualized in the 700 nm-channel.
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2.3. Purification of the conjugated sdAbs
Besides the conjugated sdAb, the reaction mixture still contains
unreacted sdAb and imaging probe, SrtA, as well as acyl-enzyme
intermediate and released His-tag that result from the first step
of the conjugation reaction. Therefore the purification protocol
consisted of (i) IMAC, to remove all undesired His-tagged prod-
ucts, (ii) EDTA competition, to prevent occupation of the chelat-
ing agents by Ca2+ or Ni2+ ions, and (iii) size-exclusion
chromatography (SEC), to separate the conjugated sdAb from
Figure 1. A) SrtA-mediated conjugation is a generic conjugation method. First, SrtA recognizes the C-terminal sortag of the sdAb and cleaves the pep-
tide bond between T and G, with release of the downstream His-tag. Next, a nucleophilic attack of the triglycine-functionalized imaging probe on the
acyl-enzyme intermediate leads to the formation of a new peptide bond with the sdAb, resulting in the site-specifically conjugated sdAb. B) Schematic
overview of the purification strategy. After SrtA-mediated conjugation the reaction mixture contains, apart from the product-of-interest (conjugated
sdAb), also unreacted sdAb, acyl-enzyme intermediate, imaging probe, SrtA and processed His-tags. Except for the imaging probe, all other undesired
products contain a His-tag. This allows to capture all His-tagged products via IMAC with Ni-sepharose beads on an FPLC system in a first purification
step. Next, the collected flow-through (composed of conjugated sdAb and imaging probe) is incubated with an excess of EDTA to remove Ca2+ ions,
that were present as a cofactor of SrtA in the reaction buffer, and Ni2+ ions, that could leak from the Ni-sepharose beads, and prevent them from
occupying the chelating agents. After sample volume reduction by concentration, the final purification step consisted of SEC on an FPLC system (inset,
chromatogram for CHX-A"-DTPA-2Rs15d is shown) to separate the product-of-interest from the excess of nucleophilic imaging probe.
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the unreacted imaging probe (Fig. 1B). The deconvoluted mass
spectra of the final purified products showed a homogeneous
population of a single-conjugated imaging tracer (Fig. 4). The
overall conversion yield of unconjugated to conjugated sdAb,
taking into account both the reaction efficiency and purification
procedure, was 48%±3% for sdAb 2Rs15d and 32%±4% for
sdAb BcII10. For a given sdAb the yield did not differ significantly
amongst the different nucleophilic imaging probes.
2.4. In vitro evaluation of the functionality after
conjugation
The functionality of the sdAb-conjugates after SrtA-mediated
conjugation was evaluated by surface plasmon resonance
(SPR). The kinetic parameters of the antigen binding were deter-
mined on immobilized HER2 recombinant protein (Table 1). All
three sdAb-conjugates CHX-A"-DTPA-2Rs15d, NOTA-2Rs15d and
Cy5-2Rs15d conserved the same affinity for the HER2 antigen
as the unconjugated starting product sdAb 2Rs15d-sortag. The
kinetic characteristics of the latter were also not influenced by
the addition of the sortag, in comparison to 2Rs15d-notag (the
sdAb without any tag, previously used in a clinical PET-study)
(16,17).
Furthermore, the fluorescence spectrum of sdAb Cy5-2Rs15d
was compared to a reference sample of Cy5 dye without penta-
peptide. To have the same dye concentrations, both samples
were diluted to obtain equal absorbance at 650 nm (Fig. 5C).
The spectrophotometric measurements showed that the fluores-
cence spectrum of the Cy5 dye was not negatively affected after
SrtA-mediated conjugation.
2.5. Radiolabeling
CHX-A"-DTPA-conjugated sdAbs, at a concentration of 10μM,
were radiolabeled with 111In (t1/2 = 68 h) with activities ranging
from 19 to 186MBq. The obtained radiochemical purity
was> 98% (Fig. 5A) and the variation in starting activity did
not affect the labeling yield. Conversely, for radiolabeling with
68Ga (t1/2 = 68min) the concentration of NOTA-conjugated sdAbs
was 2μM and it was incubated with activities ranging from 17 to
431MBq, which resulted in a radiochemical purity of> 97%
(Fig. 5B).
Prior to in vivo use the radiolabeled sdAbs were further puri-
fied by gel-filtration chromatography and filtration. The final
radiochemical purity was> 99% and the decay-corrected radio-
chemical yield after purification was 79%±2% for 111In-CHX-A"-
DTPA-2Rs15d and 71%±4% for 68Ga-NOTA-2Rs15d. The
targeting capacity of the sdAbs after the radiolabeling proce-
dures was evaluated in an in vitro cell binding study. sdAbs
111In-CHX-A"-DTPA-2Rs15d and 68Ga-NOTA-2Rs15d were still able
to bind HER2-expressing BT474M1 cells specifically, and to the
same extent as the lysine-conjugated variants (Fig. S2).
2.6. In vivo tumor targeting
Finally, the performance of the labeled sdAbs as imaging tracers
was evaluated in an in vivo tumor-targeting experiment with
BT474M1-xenografted mice. In each of the respective imaging
modalities sdAbs 111In-CHX-A"-DTPA-2Rs15d, 68Ga-NOTA-2Rs15d
and Cy5-2Rs15d were able to visualize the HER2-expressing
tumor with high contrast already 1.0 h post-injection (Fig. 6 and
S3, Movies S1 and S2). Besides the tumor also the kidneys and uri-
nary bladder can be seen which is due to the typical excretion
pattern of tracers with a molecular weight below the renal cut-
off value of 60 kDa. The ex vivo biodistribution analyses at 1.5 h
post-injection of the radiolabeled sdAbs confirmed these imaging
results (Table 2). sdAbs 111In-CHX-A"-DTPA-2Rs15d and 68Ga-
NOTA-2Rs15d targeted the tumor specifically compared to a
non-targeting control sdAb BcII10 (12.00%±4.58% injected activ-
ity per gram of tissue (IA/g) vs. 1.07%±0.51% IA/g for 111In-CHX-
A"-DTPA-2Rs15d and 111In-CHX-A"-DTPA-BcII10, respectively; and
14.07%±2.92% IA/g vs. 1.41%±1.13% IA/g for 68Ga-NOTA-
2Rs15d and 68Ga-NOTA-BcII10, respectively). The uptake was
low in all other non-targeted organs except for the kidneys. The
fast blood clearance and tumor specificity are confirmed by the
high tumor-to-blood and tumor-to-muscle ratios.
3. DISCUSSION
The site-specific labeling of targeting probes for diagnostic and
therapeutic applications is of interest to obtain a well-defined
homogeneous product with batch-to-batch consistency that
Figure 2. The imaging probes are composed of the pentapeptide H-
GGGYK-NH2 with the chelating agents CHX-A"-DTPA or NOTA, or the fluo-
rescent dye Cy5, coupled to the ɛ-amine group of the lysine residue. The
synthesis is described in supplementary material and methods.
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allows straightforward characterization and clinical translation.
Here we explored SrtA-mediated conjugation as a generic
approach for site-specific labeling of sdAbs.
The chemoenzymatic conjugation by SrtA requires the pres-
ence of the sortag LPXTG at the desired conjugation site in the
substrate protein. Upon recognition of this peptide motif, the en-
zyme cleaves the peptide bond between the threonine and gly-
cine residues, with loss of the downstream part of the substrate
protein, and then forms a new peptide bond with the N-terminal
glycine of a nucleophilic probe. In our approach the sortag
LPETG was recombinantly introduced at the C-terminal end of
the sdAb. The C-terminus is an ideal site for conjugation since
it is located opposite to the antigen-binding site (18), hereby
avoiding antigen-binding interference, and it renders the
strategy generic. The inclusion of a His-tag downstream of the
sortag allowed purification of the sdAb via IMAC during sdAb
production, while it resulted in the loss of the His-tag upon con-
jugation. The latter is a great advantage for clinical translation
where the use of His-tagged proteins is avoided since they
increase the possible risk of immune responses (19). Of note,
the safety profile of the use of SrtA-mediated conjugation in clin-
ical tracer production, and in particular the non-immunogenic
character of the sortag and absence of metal contaminants com-
ing from the IMAC step in purification, still needs to be verified.
Another important aspect for a generic labeling method is the
flexibility of SrtA towards its nucleophilic substrates. Antibodies
and antibody-derived fragments have already been functional-
ized with fluorescent labels for in vitro detection (20,21), as well
Figure 3. Determination of the reaction efficiency for conjugation of CHX-A"-DTPA (left), NOTA (middle) and Cy5 (right) to sdAb 2Rs15d. The contents
of the reaction mixture were varied as indicated with + (present) and – (absent). The concentrations used were 50 μM sdAb 2Rs15d-sortag, 150 μM SrtA
and 1.5mM imaging probe. The reaction mixture was incubated overnight. The anti-His-tag Western blot (A and B) detects all His-tagged products in
the reaction mixtures (unreacted sdAb, SrtA and acyl-enzyme intermediate). In the absence of imaging probe there was a clear accumulation of acyl-
enzyme intermediate since the reaction could not proceed. When all three reaction components were present a high sdAb substrate consumption was
obtained (≥ 75%), as shown by the weaker sdAb band compared to the control reaction that only contained sdAb substrate. The Coommassie staining
of the corresponding LDS-PAGE (C) is shown as a control for the total amount of sdAb loaded, as both His-tagged and conjugated (without His-tag)
sdAbs are visible. In the 700 nm fluorescence channel (D) the successful conjugation of Cy5 to sdAb 2Rs15d was visualized (saturated signal). The band
with an apparent molecular weight between 55 and 70 kDa probably corresponds to a dimeric form of SrtA, which was reported before to be visible in
reducing sodium dodecyl sulphate PAGE (15).
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as with toxins and polymeric capsules for targeted drug delivery
(22–24). The feasibility of installing bioorthognal click chemistry
handles gave rise to even more opportunities, including the gen-
eration of C-terminus-to-C-terminus sdAb dimers (25) and the
oriented immobilization on nanosheets (26), without sterical hin-
drance of the antigen-binding regions upon dimerization or
immobilization. Not surprisingly, SrtA-mediated conjugation also
found its way into the field of in vivo molecular imaging. So far it
was employed for the functionalization of scFv’s (single-chain
variable fragment) and sdAbs with iron oxide particles for use
in magnetic resonance imaging (MRI) (27), microbubbles for ul-
trasound imaging (28) and the radiolabels 64Cu and 18F for PET
Figure 4. The purified sdAb-conjugates CHX-A"-DTPA-2Rs15d (A), NOTA-2Rs15d (B) and Cy5-2Rs15d (C) are homogeneous single-conjugated sdAbs.
Unreacted sdAb (14,430.0 Da), SrtA (22,133.9 Da) and the acyl-enzyme intermediate (35,182.5 Da) are absent in the ESI-Q-ToF deconvoluted mass spec-
tra. In (A) and (B), complexation of Fe by the chelating agents is seen (net change in calculated mass of + 52.8 Da). However, this did not interfere with
further radiolabeling. (†: Peak arising from artifact in deconvolution)
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(29–32). Here we applied SrtA-mediated conjugation for the site-
specific labeling of sdAbs with 111In, 68Ga and Cy5 to produce
imaging tracers for SPECT, PET and FRI, respectively. Together
with the aforementioned reports this demonstrates the versatil-
ity and efficacy of SrtA to produce imaging tracers for multiple
non-invasive in vivo imaging modalities.
The pentapeptide H-GGGYK-NH2 formed the base of the im-
aging probes. It contained an N-terminal triglycine to fulfill the
nucleophilic attack in the chemoenzymatic reaction and a lysine
residue for side chain conjugation of the chelating agents CHX-
A"-DTPA-NCS or NOTA-NCS, or the fluorescent dye Cy5. We pre-
ferred the employment of the side chain ɛ-amine of lysine as
the acceptor for carboxylated chelating agents and fluorescent
dyes, over the side chain sulfhydryl of cysteine as acceptor for
maleimide-functionalized probes, to avoid the introduction of
a potentially reversible thioether succinimide linkage (33,34).
This thioether succinimide linkage probably does not affect
diagnostic imaging with low molecular weight imaging tracers
at early time points after injection, but should certainly be
avoided for targeted radionuclide therapy with longer-lived
isotopes.
After optimization of the substrate concentrations and incuba-
tion time, the conjugation was carried out in an overnight reac-
tion with a threefold molar excess of SrtA and a thirtyfold
molar excess of imaging probe, relative to the sdAb concentra-
tion, and resulted in a sdAb substrate consumption above 75%.
These results were obtained with the solubilized form of the wild
type SrtA from S. aureus (35). However, the use of a mutant form
of SrtA with an improved catalytic activity could still increase this
reaction efficiency and would allow to lower product consump-
tion (36). After the purification of the conjugated sdAb the over-
all efficiency of the procedure was 30 to 50%, meaning that a
reaction starting with 1.0 mole of sdAb yields 0.3 to 0.5 mole
of purified, conjugated product. Mass spectrometry analysis of
the conjugated sdAbs confirmed that only one chelating agent
or fluorescent dye was attached, and did not detect the presence
of any unreacted substrate or side-product. For CHX-A"-DTPA-
and NOTA-conjugated sdAbs complexation with Fe was de-
tected, probably arising from Fe contamination in the buffers
used for conjugation. Contrary to the radiolabeling buffers, the
conjugation reaction buffer was not treated against metal
contamination since this would interfere with the Ca2+ concen-
tration, a necessary cofactor of SrtA. An alternative could be to
use a Ca2+-independent form of SrtA derived from another bac-
terial strain (e.g. Streptococcus pyogenes) (37) or by mutation of
the SrtA from S. aureus (38). Nevertheless, the Fe-contamination
did not interfere with radiolabeling as high radiochemical
Figure 5. SrtA-mediated conjugation does not interfere with
radiolabeling or the spectral characteristic of the fluorescent dye. RP-
HPLC analysis of 111In-CHX-A"-DTPA-2Rs15d (A) and 68Ga-NOTA-2Rs15d
(B) showed a high radiochemical purity after radiolabeling. The γ-spec-
trum chromatogram of a representative experiment is shown (3min: free
111In or 68Ga; 13min: radiolabeled sdAb). C) Spectrophotometric charac-
terization of sdAb Cy5-2Rs15d compared to unconjugated Cy5 dye (with-
out pentapeptide) as a standard. For two samples having the same dye
concentration (equal absorbance spectra), the increased intensity of the
fluorescence spectrum of Cy5-2Rs15d showed that the Cy5 dye is not
stacked after conjugation to sdAb 2Rs15d.
Table 1. The kinetic parameters of sdAb 2Rs15d are pre-
served after SrtA-mediated conjugation with CHX-A"-DTPA,
NOTA or Cy5
ka
105M-1 s-1
kd
10-4 s-1
KD
10-9 M
Chi2
RU2
2Rs15d-notag 1.8 7.0 3.8 0.07
2Rs15d-sortag 1.5 5.1 3.4 0.11
CHX-A"-DTPA-2Rs15d 1.5 5.4 3.7 0.16
NOTA-2Rs15d 1.4 5.3 3.7 0.09
Cy5-2Rs15d 1.5 6.1 4.1 0.14
SPR measurements are performed on immobilized HER2
recombinant protein. The kinetic parameters of 2Rs15d-
notag (the sdAb without any tag) (16) and 2Rs15d-sortag
are given as a reference.
(ka, association reaction rate constant; kd, dissociation
reaction rate constant; KD, dissociation equilibrium constant;
RU, resonance units; all values had SE< 0.1)
SORTASE A-MEDIATED SITE-SPECIFIC LABELING OF SDABS
Contrast Media Mol. Imaging (2016) Copyright © 2016 John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/cmmi
purities (>97%) were obtained at the end of the radiolabeling
reactions.
The SrtA-mediated labeling strategy was set up and validated
in a HER2-positive xenografted cancer model. HER2 is a type 1
transmembrane receptor which is overexpressed in approxi-
mately 20% of breast cancer patients and is associated with
low overall survival (39). Therefore the development of personal-
ized anti-HER2 therapeutic strategies and methods for identifica-
tion of patients that would benefit from those therapies is of
utmost interest. Previously sdAb 2Rs15d, which was developed
against HER2, has shown preclinically to be an excellent
targeting agent for such purposes (16,40,41), and a PET-CT proto-
col with 68Ga-(NOTA)1.5-2Rs15d was recently found safe in a clin-
ical phase 1 study (17). Initial characterization of the anti-HER2
binders and the selection of a lead compound was done with
99mTc-labeled sdAbs (41). Although it is a convenient and site-
specific labeling method for preclinical screening of His-tagged
sdAbs (42), 99mTc-tricarbonyl chemistry has a rather limited
applicability in a context of multiple imaging modalities. Alterna-
tively, sdAb 2Rs15d was randomly conjugated on lysine residues
without loss of targeting efficacy (16), which was confirmed in a
direct comparison between randomly and site-specifically conju-
gated sdAbs in the in vitro cell binding assay in this study and in
previous work (5). Of note, the sdAb 2Rs15d was originally
selected because of the absence of lysine residues in the
antigen-binding region. Such criterion is however a big burden,
as for example in the case of our anti-HER2 sdAbs where it
excluded seven out of the seventeen identified families (unpub-
lished data from Vaneycken et al.) (41). The availability of a ge-
neric site-specific labeling method via a C-terminal sortag omits
the need for such an exclusion criterion in future lead compound
selections.
Figure 6. sdAb 2Rs15d targets HER2-positive BT474M1 tumors in mice, leading to high contrast in multiple imaging modalities, already at 1.0 h post-
injection. Maximum-intensity-projections are shown for SPECT-CT and PET-CT, 2D dorsal view is shown for FRI.
Table 2. sdAbs 111In-CHX-A"-DTPA-2Rs15d and 68Ga-NOTA-2Rs15d show a significant tumor uptake in HER2-expressing BT474M1-
xenografts compared to non-targeting control sdAbs, with low uptake in all other non-targeted organs except kidneys (renal
excretion)
111In-CHX-A"-DTPA-2Rs15d 111In-CHX-A"-DTPA-BcII10 68Ga-NOTA-2Rs15d 68Ga-NOTA-BcII10
Blood 0.46 ± 0.23 0.61 ± 0.25 0.41 ± 0.07 0.29 ± 0.15
Heart 0.21 ± 0.06 0.29 ± 0.09 0.21 ± 0.04 0.18 ± 0.10
Lungs 0.46 ± 0.16 0.72 ± 0.22 0.92 ± 0.25 0.71 ± 0.08
Liver 0.33 ± 0.08 0.37 ± 0.12 0.32 ± 0.18 0.35 ± 0.05
Spleen 0.16 ± 0.04 0.19 ± 0.07 0.24 ± 0.06 0.17 ± 0.08
Pancreas 0.12 ± 0.03 0.16 ± 0.05 0.16 ± 0.04 0.11 ± 0.05
GI tract† 0.68 ± 0.26 0.76 ± 0.06 1.07 ± 0.53 0.66 ± 0.14
Kidney 117.99 ± 5.13 * 213.84 ± 10.26 124.68 ± 13.92 137.40 ± 34.32
Muscle 0.62 ± 0.68 0.29 ± 0.14 0.26 ± 0.05 0.28 ± 0.06
Bone 0.36 ± 0.37 0.25 ± 0.05 0.31 ± 0.07 0.48 ± 0.53
Tumor 12.00 ± 4.58 * 1.07 ± 0.51 14.07 ± 2.92 * 1.41 ± 1.13
Tumor-to-Blood 31.19 ± 15.84 * 1.94 ± 0.96 34.50 ± 4.24 * 6.33 ± 6.57
Tumor-to-Muscle 30.70 ± 21.01 * 4.01 ± 1.61 55.58 ± 8.63 * 5.20 ± 4.45
The biodistribution profile was determined ex vivo at 1.5 h post-injection and is expressed as % IA/g ± SD.
(GI tract, gastrointestinal tract)
†: % IA is given
*: p< 0.01 compared to the non-targeting control sdAb BcII10; n = 5–6
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Here we employed SrtA-mediated conjugation for the site-
specific labeling of sdAb 2Rs15d with 111In, 68Ga and Cy5. In
the three corresponding imaging modalities SPECT-CT, PET-CT
and FRI, respectively, the 2Rs15d-conjugates were able to visual-
ize the HER2-positive tumor in BT474M1 xenografts with high
contrast as early as 1 h post-injection. The ex vivo biodistribution
analysis of 111In-CHX-A"-DTPA-2Rs15d and 68Ga-NOTA-2Rs15d
confirmed the conservation of the targeting efficiency after
SrtA-mediated conjugation, with a high and specific tumor up-
take at 90min post-injection and low background in all other
non-targeted organs, except kidneys. The difference in kidney re-
tention between 111In-CHX-A"-DTPA-2Rs15d and 111In-CHX-A"-
DTPA-BcII10 can be partially attributed to the difference in sdAb
protein sequence. However, the 68Ga labeled compound does
not show such a profound difference, so the influence of the
chelating agent and radiolabel should not be neglected. Further-
more 68Ga-NOTA-2Rs15d showed a higher kidney uptake com-
pared to the lysine conjugated 68Ga-(NOTA)1.5-2Rs15d (16),
while both sdAb derivatives lack a His-tag. This indicates the pos-
sible influence of the applied conjugation method on kidney
retention during tracer elimination and should be investigated
further. Also, the use of SrtA-mediated labeling can be further ex-
plored for targeted radionuclide therapy by radiolabeling of the
chelating agent CHX-A"-DTPA with 177Lu (43), or by conjugating
other chelating agents or functional groups to the pentapeptide
of the nucleophlic probe.
4. CONCLUSION
We presented a detailed SrtA-mediated site-specific labeling ap-
proach of sdAbs for subsequent application in non-invasive
in vivomolecular imaging. This labeling strategy resulted in a ho-
mogeneous, site-specifically single-conjugated tracer with
uncompromised functionality. We illustrated its versatility by
conjugating three different imaging probes for three different
in vivo imaging modalities. The introduction of the sortag at
the C-terminal end of the sdAb makes this strategy a generic ap-
proach for a wide range of future site-specific labelings of sdAbs.
5. EXPERIMENTAL
5.1. Recloning, expression and production of sdAbs
The generation and biochemical characterization of the anti-
HER2 sdAb 2Rs15d and the non-targeting control sdAb BcII10
(developed against bacterial beta-lactamase) have been de-
scribed previously (41,44). The NcoI – BstEII digested PCR frag-
ment, encoding the sdAb region, was ligated in-frame into the
pHEN29 plasmid, cut with the same restriction enzymes. The
pHEN29 expression vector is derived from the pHEN6 vector,
an Escherichia coli expression plasmid containing the pelB signal
sequence to translocate the recombinant protein with a C-
terminal His-tag to the periplasm (44). In the pHEN29 expression
vector, the sortag LPETG codons are inserted between the sdAb
and His-tag codons, which are followed by the EPEA codons for
an E-tag (Fig. S4).
The sdAbs were produced in bacteria containing the pHEN29
recombinant expression plasmid and purified from the peri-
plasm by IMAC and SEC, as described in detail elsewhere (45).
In short, sdAbs were translocated to the periplasm of E. coli
WK6 cells, from which they were collected with an osmotic
shock. sdAbs were purified from the periplasmic extract via IMAC
with HIS-select suspension (Sigma-Aldrich, Saint Louis, MO, USA)
and subsequent SEC on a HiLoad 16/600 Superdex 75 PG column
(GE Healthcare, Uppsala, Sweden) equilibrated in PBS (pH 7.4).
The sdAb concentrations were determined spectrophotomet-
rically at 280 nm using the theoretically calculated extinction co-
efficient (46).
An in silico predicted structure of sdAb 2Rs15d was generated
using ESyPred3D (47).
5.2. SrtA-mediated conjugation
Prior to SrtA-mediated conjugation the buffer of the sdAbs was
changed to 50mM Tris-HCl (pH 7.9), 150mM NaCl using a
Vivaspin 2 concentrator (MWCO 5000) (Sartorius) according to
the manufacturer’s protocol. The lyophilized nucleophilic probes
were dissolved in 50mM Tris-HCl (pH 7.9), 150mM NaCl as a
10mM stock solution.
For optimization of the conjugation reaction, small-scale reac-
tions were set up in 40μL with variable concentrations of SrtA
and nucleophilic probe and variable incubation times.
The most optimal conditions were upscaled to a volume of
1.5mL. The reaction mixture was composed of 50μM sdAb,
150μM SrtA and 1.5mM nucleophilic probe, with 50mM Tris-
HCl (pH 7.9), 150mM NaCl, 10mM CaCl2 as the reaction buffer.
The reaction was allowed to take place overnight at 37 °C.
5.3. Reducing lithium dodecyl sulphate polyacrylamide gel
electrophoresis (LDS-PAGE) and Western blot
Samples from overnight reaction mixtures containing 5μg sdAb
were mixed with NUPAGE LDS sample buffer and NUPAGE sam-
ple reducing agent (Life technologies, Carlsbad, CA, USA) accord-
ing to the manufacturer’s protocol. After incubation at 70 °C for
10min, samples were run on a NUPAGE 12% Bis-Tris gel (Life
technologies) in MES buffer. PageRuler prestained protein ladder
(Thermo Fisher Scientific, Rockford, IL, USA) was used as molecu-
lar weight marker. When complete separation was obtained the
gel was stained with Coomassie Brilliant Blue for total protein vi-
sualization or further processed in Western blot to reveal His-
tagged products. For the latter, proteins were transferred from
the LDS polyacrylamide gel to a 0.45μm nitrocellulose mem-
brane (GE Healthcare). The residual protein binding sites on the
membrane were subsequently blocked by incubation in PBS
(pH 7.4) supplemented with milk powder (2%) for 2 h at 4 °C.
His-tagged products were detected by using mouse anti-
histidine tag (AbD Serotec, Oxford, UK) as the primary antibody
and goat anti-mouse IgG peroxidase conjugate (Sigma-Aldrich)
(only for CHX-A"-DTPA and NOTA conjugates) or goat anti-
mouse IgG-IrDye800CW (LI-COR) as the secondary antibody, with
thorough washing with PBS-Tween (0.05%) (pH 7.4) in between.
Western blots where the peroxidase-conjugated detection anti-
body was used, were developed using 4-chloro-1-napthol
(Sigma-Aldrich). The IrDye800CW-conjugated detection antibody
was visualized using an Odyssey imaging scanner (LI-COR, Lin-
coln, NE, USA) at 800 nm.
Intensities of the sdAb bands were determined by measuring
the integrated intensities in the 800 nm-channel with the Odys-
sey imaging software (LI-COR).
5.4. Purification of the conjugated sdAbs
In the first step of the purification procedure all His-tagged prod-
ucts were captured from the reaction mixture via IMAC, using a
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1mL HisTrap HP column (GE Healthcare). The purification was
done in three runs (injection of 500μL reaction mixture per run)
with 50mM Tris-HCl (pH7.9), 150mM NaCl as running buffer at a
flow rate of 0.3mL/min. The flow-through was collected based
on its absorption of UV light at 280 nm. Subsequently the collected
flow-through was incubated with 15mM EDTA (final concentra-
tion) for 30min at 37 °C. Prior to SEC purification, the sample’s vol-
ume was reduced using a Vivaspin 2 device (MWCO 5000)
(Sartorius, Goettingen, Germany) according to the manufacturer’s
protocol. The SEC purification was performed on a Superdex 75
10/300 GL column (GE Healthcare) at a flow rate of 0.5mL/minwith
elution in 0.1M NH4OAc (pH7.0) (treated with Chelex-100 (Sigma-
Aldrich)) for CHX-A"-DTPA- and NOTA-conjugated sdAbs, and in
PBS (pH 7.4) for Cy5-conjugated sdAbs. The overall yield was deter-
mined by comparison of the moles of purified conjugate to the
moles of sdAb used to start the reaction.
5.5. Electrospray ionization quadrupole time-of-flight (ESI-
Q-ToF) mass spectrometry of purified sdAb-conjugates
Samples were desalted using an Amicon device (MWCO 3000)
(Merck Millipore, Darmstadt, Germany) according to the manufac-
turer’s protocol and placed in 25mM NH4OAc buffer. The samples
were analyzed on an ESI-Q-ToF (Waters, Milford, MA, USA) in posi-
tive ion mode at an estimated protein concentration of 10μM in
25mM NH4OAc, 30% acetonitrile, 0.5% formic acid. Spectra
deconvolution technique was the maximum entropy Max ent1.
Theoretical masses were calculated using ChemBioDraw Ultra
14.0 (PerkinElmer, Waltham, MA, USA).
5.6. SPR
The kinetic parameters of antigen binding by sdAb 2Rs15d and
sdAb-conjugates were determined via SPR with a Biacore T200
(GE Healthcare). The HER2-Fc recombinant fusion protein (Sino
Biologicals, Beijing, China) was immobilized in 10mM sodium ac-
etate (pH 4.5) on a CM5 chip (GE Healthcare) via amine coupling
chemistry to 740 response units. sdAbs were analysed in a two-
fold serial dilution (125 nM – 0.488 nM) in HBS with an analyte
flow rate of 10μL/min. The association phase took 180 s and
the dissociation phase 600 s. Binding curves were fitted using a
‘1:1 (antigen:analyte) with drift and RI2’ binding model in Biacore
T200 evaluation software.
5.7. UV-VIS and fluorescence spectrophotometric mea-
surements of Cy5-conjugated sdAb
A sample of Cy5-2Rs15d was prepared in H2O in a 3.0mL quartz
cuvette, reaching an absorbance below 0.1 at 650 nm (approxi-
mately 0.3μM). Then a sample of the unconjugated Cy5 dye
(without pentapeptide) was prepared with the same absorbance
at 650 nm. Both samples were measured with an Ultrospec3000
UV-VIS spectrophotometer (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). The fluorescent output of both samples
was measured with a LS55 fluorescence spectrometer (Perkin
Elmer). The samples were excited at 650 nm and emission light
was measured between 630 and 750 nm, with the excitation slit
at 10 nm and the emission slit at 7 nm.
5.8. Radiolabeling procedures
Buffers used for radiolabeling were purified from metal contam-
inants with Chelex-100 (Sigma-Aldrich).
CHX-A"-DTPA-conjugated sdAbs were radiolabeled with InCl3
(Mallinckrodt Pharmaceuticals) (19 to 186MBq) at a final sdAb
concentration of 10μM in reaction volumes of 100 to 500μL with
0.2M NH4OAc buffer (pH 5.0). After incubation for 30min at 50 °
C, the radiochemical purity was determined via instant thin-layer
chromatography (iTLC) on silica gel (Pall Corporation, Port Wash-
ington, NY, USA) with 0.1M sodium citrate (pH 5.0) as eluent.
68Ga was eluted in 0.1 N HCl from a 68Ge/68Ga generator
(Eckert & Ziegler, Berlin, Germany). NOTA-conjugated sdAbs
were diluted in 0.1 to 1.0mL sodium acetate (0.1M, pH 5.0) and
mixed with an equal volume of the 68Ga-eluate (17 to
431MBq), to obtain a final sdAb concentration of 2μM. After in-
cubation for 10min at 37 °C, the radiochemical purity was deter-
mined via iTLC as described above.
Prior to in vivo use the radiolabeled tracers were purified via
gel-filtration chromatography on Illustra NAP-5 or PD-10
desalting columns (both from GE Healthcare), for 111In- and
68Ga-radiolabeled tracers, respectively, with elution in PBS-
Tween (0.1%) (pH 7.4) according to the manufacturer’s protocol.
Finally, they were passed through a 0.22μm PVDF membrane
filter (Merck Millipore).
5.9. RP-HPLC
RP-HPLC analysis of the radiolabeled sdAbs was performed on a
polystyrene divinylbenzene copolymer column (PLRP-S 300Å,
5μm, 250/4mm; Varian, Santa Clara, CA, USA). The following gra-
dient was used (A: H2O, 0.1% trifluoroacetic acid; B: acetonitrile,
0.1% trifuoroacetic acid): 0 – 5min, 75%A/25% B; 5 – 7min,
75%A/25%B – 66%A/34% B; 7 – 10min, 66%A/34%B – 100% B;
10–20min, 100% B; at a flow rate of 1mL/min.
5.10. Animal models
All animal study protocols were approved by the Ethical commit-
tee for animal experiments of the Vrije Universiteit Brussel. All
manipulations were done under the control of 2.5% isoflurane
(Abbott, Abbott Park, IL, USA). Female athymic nude mice
(Charles River, Sulzfeld, Germany) received an estrogen pellet
(0.36mg 17β-estradiol, 60-day release) (Innovative Research of
America, Sarasota, FL, USA) that was placed subcutaneously in
the neck region. The next day the mice were inoculated subcuta-
neously in the right hind leg with 5x106 BT474M1 cells in 100μL
growth medium (cell culturing conditions in supplementary ma-
terial and methods), mixed with 100μL Matrigel basement mem-
brane matrix (Corning, Tewksbury, MA, USA). Tumors were
grown for 4weeks. Tumor sizes ranged from 20 to 335mm3.
5.11. In vivo imaging and ex vivo biodistribution analysis
of radiolabeled tracers
BT474M1-xenografted mice (n = 5-6) were intravenously injected
under the control of 2.5% isoflurane (Abbott). For SPECT-CT (sin-
gle-photon emission computed tomography – X-ray computed
tomography) acquisition and subsequent ex vivo biodistribution
analysis they were administered 16MBq of 111In-CHX-A"-DTPA-
2Rs15d (31MBq/nmol) or 111In-CHX-A"-DTPA-BcII10 (38MBq/
nmol). For ex vivo biodistribution analysis of the 68Ga-labeled
compounds they received 5MBq of 68Ga-NOTA-2Rs15d
(21MBq/nmol) or 68Ga-NOTA-BcII10 (19MBq/nmol). For PET-CT
(positron emission tomography – X-ray computed tomography)
acquisition the administered dose was increased (11MBq,
37MBq/nmol).
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SPECT-CT and PET-CT acquisition and reconstruction details
are described in supplementary material and methods. Images
were analysed using OsiriX (Pixmeo, Bernex, Switzerland).
Animals were dissected at 1.5 h post-injection. Organ activities
were measured against a standard of known activity with a
gamma counter (Cobra II inspector 5003, Canberra-Packard,
Downers Grove, IL, USA) and expressed as % IA/g, corrected for
decay and paravenous activity in the tail.
5.12. In vivo imaging analysis of Cy5-labeled tracers
BT474M1-xenografts (n = 3), fed on a low-fluorescent diet (2016
Teklad Global 16% Protein Rodent Diet, Harlan, Indianapolis, IN,
USA), were intravenously injected under the control of 2.5%
isoflurane (Abbott) with 2 nmol of Cy5-2Rs15d or Cy5-BcII10.
At 1.0 h post-injection, animals were anesthetized with 2.5%
isoflurane (Abbott) and positioned in a fluorescence imaging sys-
tem (FMT2500, PerkinElmer). Reflectance images of the dorsal
and ventral side of the animals were acquired in the 635 nm
channel. Images were analyzed using TrueQuant (PerkinElmer).
5.13. Statistical analysis
The statistical analysis was performed in SPSS Statistics 22 (IBM,
Chicago, IL, USA). Ex vivo biodistribution data were analysed
using a nonparametric Mann-Whitney U test for two indepen-
dent samples.
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